Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in J Clin Invest

Retrieve available abstracts of 15 articles:
HTML format
Text format



Single Articles


    April 2018
  1. GONG K, Guo G, E Gerber D, Gao B, et al
    TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.
    J Clin Invest. 2018 Apr 3. pii: 96148. doi: 10.1172/JCI96148.
    PubMed     Text format     Abstract available


    February 2018
  2. TOUAT M, Sourisseau T, Dorvault N, Chabanon RM, et al
    DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.
    J Clin Invest. 2018 Feb 15. pii: 90277. doi: 10.1172/JCI90277.
    PubMed     Text format     Abstract available


    January 2018
  3. CHOCKLEY PJ, Chen J, Chen G, Beer DG, et al
    Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.
    J Clin Invest. 2018 Jan 11. pii: 97611. doi: 10.1172/JCI97611.
    PubMed     Text format     Abstract available


    October 2017
  4. WEI Y, Kim TJ, Peng DH, Duan D, et al
    Fibroblast-specific inhibition of TGF-beta1 signaling attenuates lung and tumor fibrosis.
    J Clin Invest. 2017;127:3675-3688.
    PubMed     Text format     Abstract available


    August 2017
  5. JESCHKE J, Bizet M, Desmedt C, Calonne E, et al
    DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.
    J Clin Invest. 2017;127:3090-3102.
    PubMed     Text format     Abstract available


  6. WANG YT, Chen J, Chang CW, Jen J, et al
    Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.
    J Clin Invest. 2017;127:2982-2997.
    PubMed     Text format     Abstract available


  7. AYERS M, Lunceford J, Nebozhyn M, Murphy E, et al
    IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade.
    J Clin Invest. 2017;127:2930-2940.
    PubMed     Text format     Abstract available


    June 2017
  8. SHENOLIKAR S
    A SMAP in the face for cancer.
    J Clin Invest. 2017;127:2048-2050.
    PubMed     Text format     Abstract available


    August 2016
  9. LARSEN JE, Nathan V, Osborne JK, Farrow RK, et al
    ZEB1 drives epithelial-to-mesenchymal transition in lung cancer.
    J Clin Invest. 2016 Aug 8. pii: 76725. doi: 10.1172/JCI76725.
    PubMed     Text format     Abstract available


    June 2016
  10. WEISKOPF K, Jahchan NS, Schnorr PJ, Cristea S, et al
    CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
    J Clin Invest. 2016 Jun 13. pii: 81603. doi: 10.1172/JCI81603.
    PubMed     Text format     Abstract available


    May 2016
  11. CHEN Z, Li JL, Lin S, Cao C, et al
    cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
    J Clin Invest. 2016 May 3. pii: 85250. doi: 10.1172/JCI85250.
    PubMed     Text format     Abstract available


    February 2016
  12. JACQUELOT N, Enot DP, Flament C, Vimond N, et al
    Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.
    J Clin Invest. 2016 Feb 8. pii: 80071. doi: 10.1172/JCI80071.
    PubMed     Text format     Abstract available


    December 2015
  13. EDMONDS MD, Boyd KL, Moyo T, Mitra R, et al
    MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer.
    J Clin Invest. 2015 Dec 14. pii: 82720. doi: 10.1172/JCI82720.
    PubMed     Text format     Abstract available


  14. SUZUKI M, Cao K, Kato S, Komizu Y, et al
    Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.
    J Clin Invest. 2015 Dec 7. pii: 79775. doi: 10.1172/JCI79775.
    PubMed     Text format     Abstract available


  15. KONG R, Yi F, Wen P, Liu J, et al
    Myo9b is a key player in SLIT/ROBO-mediated lung tumor suppression.
    J Clin Invest. 2015;125:4407-20.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: